From the *Rheumatology Clinic, Nazareth Hospital, Nazareth; and Department of Medicine, Carmel Medical Center, Haifa; †Department of Radiology, Nazareth Hospital, Nazareth; ‡Department of Medicine, Carmel Medical Center, Haifa; §Department of Orthopedics, and ||Central Laboratory, Nazareth Hospital, Nazareth, Israel.
J Investig Med. 2013 Oct;61(7):1104-7. doi: 10.2310/JIM.0b013e3182a67871.
Intra-articular corticosteroid injection (IACI) of betamethasone depot preparation is a popular procedure at the knee joint. Intra-articular corticosteroid injection in general could be associated with systemic effects including suppression of the hypothalamic-pituitary-adrenal axis. There are nearly no reports on the effect of IACI of betamethasone at the knee joint on the hypothalamic-pituitary-adrenal axis.
Consecutive patients attending the rheumatology or orthopedic clinic with osteoarthritic knee pain who were not responding satisfactorily to medical and physical therapy were allocated to group 1 after consent and given IACI of 6 mg of betamethasone acetate/betamethasone sodium phosphate. After completion of this part, consecutive age- and sex-matched patients were allocated to group 2 and given intra-articular injection of 60 mg of sodium hyaluronate. Demographic, clinical, laboratory, and radiographic variables were documented. Just before the knee injection and 1, 2, 3, 4, and 8 weeks later, patients had 1-μg adrenocorticotropin hormone (ACTH) stimulation test. Secondary adrenal insufficiency (SAI) was defined as levels of less than 18 µg/dL and lack of a rise of more than 6 µg/dL in serum cortisol level, 30 minutes after the ACTH stimulation test.Patients were blinded to the injected material, and all injections were ultrasound guided.
Twenty patients were enrolled in each group and equally divided between the 2 sexes. The mean age of the patients was approximately 54 years in both groups. No significant difference in any variable was seen between the 2 groups. One patient only from group 1 (the betamethasone group) had SAI 3 weeks after the IACI compared to none in the control group (P > 0.9999). His serum cortisol level 30 minutes after the ACTH stimulation was 17 µg/dL, with a rise of 3 µg/dL from baseline.
Intra-articular corticosteroid injection of 6 mg of betamethasone acetate/betamethasone sodium phosphate at the knee joint was not significantly associated with SAI at the time points tested.
关节内注射倍他米松储库制剂(IACI)是膝关节的常用治疗方法。一般来说,关节内注射皮质类固醇可能与全身效应有关,包括下丘脑-垂体-肾上腺轴的抑制。几乎没有关于膝关节内注射倍他米松对下丘脑-垂体-肾上腺轴影响的报道。
连续就诊于风湿病或矫形外科诊所的膝关节骨关节炎疼痛患者,在知情同意后接受 6 毫克倍他米松醋酸盐/倍他米松磷酸钠的 IACI,并在治疗完成后,连续纳入年龄和性别匹配的患者至第 2 组,接受 60 毫克透明质酸钠的关节内注射。记录患者的人口统计学、临床、实验室和影像学变量。在膝关节注射前以及注射后 1、2、3、4 和 8 周,患者进行 1-μg 促肾上腺皮质激素(ACTH)刺激试验。继发性肾上腺功能不全(SAI)定义为血清皮质醇水平低于 18 µg/dL,且 ACTH 刺激试验 30 分钟后血清皮质醇水平升高不足 6 µg/dL。患者对注射药物不知情,所有注射均在超声引导下进行。
每组纳入 20 例患者,男女各 10 例。两组患者的平均年龄均约为 54 岁。两组间无任何变量的显著差异。仅第 1 组(倍他米松组)的 1 例患者在 IACI 后 3 周出现 SAI,而对照组无患者出现 SAI(P>0.9999)。该患者的 ACTH 刺激后 30 分钟血清皮质醇水平为 17 µg/dL,与基线相比升高了 3 µg/dL。
膝关节内注射 6 毫克倍他米松醋酸盐/倍他米松磷酸钠与测试时的 SAI 无明显相关性。